Product News
Filter News
Found 274,360 articles
-
Raigmore Hospital in Scotland selects RayCare
4/17/2024
RaySearch Laboratories AB is pleased to announce that Raigmore Hospital in Inverness, Scotland has placed an order for the oncology information system RayCare®.
-
Sanochemia: New contrast agent aims to detect the smallest lymphatic metastases in prostate cancer
4/17/2024
Sanochemia Pharmazeutika secures exclusive licensing rights to a new MRI contrast agent based on ferumoxtran, that is in an advanced pivotal trial in clinical phase III and may be used to detect the smallest lymph node metastases in prostate cancer patients.
-
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
4/17/2024
Genetic Technologies Limited is pleased to announce the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand.
-
BillionToOne Mitigating RhoGAM(R) Shortage With Unity Fetal RhD™ Non-invasive Prenatal Test
4/17/2024
BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, has reached a milestone of testing over 80,000 patients for Rh incompatibility, which develops when a pregnant patient has Rh-negative blood and the baby has Rh-positive blood.
-
Mill Creek's Frontier Dermatology Is First in Washington to Offer Nonsurgical Treatment for Common Skin Cancer Using Image-Guided Superficial Radiation Therapy
4/17/2024
SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy, a nonsurgical treatment with the highest cure rate for common skin cancers, announced its availability in Washington at an event at Frontier Dermatology in Mill Creek.
-
InnoGI Technologies and Simulations Plus Combine Forces to Offer Next-Level Modeling Solutions for the Prediction of Oral Drug Performance
4/17/2024
InnoGI Technologies (formerly The TIM Company) is pleased to announce an exciting, market-driven collaboration with Simulations Plus to combine its TIM Technology, part of the InnoGI SurroGUT ™ platform, with the GastroPlus ® and ADMET Predictor ® modelling software offered by Simulations Plus.
-
Cardiovascular Centers of America Announces Cardiac Ablation Service Line at Advanced Heart and Vascular in Deltona, Florida
4/17/2024
Cardiovascular Centers of America proudly announces the launch of Florida's the first complete cardiac ablation service line in an Ambulatory Surgery Center at Advanced Heart and Vascular Surgery Center.
-
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
4/17/2024
ABVC BioPharma, Inc. announced today that the Company, together with its affiliate Rgene Corporation entered into a comprehensive licensing agreement with OncoX.
-
SalioGen Therapeutics Announces Selection of Development Candidate for ABCA4-mediated Stargardt Disease
4/17/2024
SalioGen Therapeutics today announced the nomination of a development candidate, SGT-1001, for the treatment of Stargardt disease, a rare and progressive inherited retinal disease.
-
X-Therma Announces XT-Thrive® Drug Master File (DMF) Accepted by U.S. Food and Drug Administration (FDA)
4/17/2024
X-Therma Inc , announces that the Food and Drug Administration (FDA) accepted a Drug Master File (DMF) covering its product, XT-Thrive ® .
-
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
4/17/2024
Hyperfine, Inc. today announced that the first patients have been enrolled in the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) observational study.
-
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
4/17/2024
Artiva Biotherapeutics, Inc., a clinical-stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the first patient has been dosed in its Phase 1 trial of AlloNK®.
-
IGM Biosciences Announces Refocusing of Sanofi Collaboration
4/17/2024
IGM Biosciences, Inc. today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets.
-
Scopio Labs Receives Groundbreaking FDA Clearance for First-Ever Digital Bone Marrow Aspirate Application
4/17/2024
Scopio Labs today announced that it has been granted De Novo clearance by the U.S. Food and Drug Administration (FDA) for its Full-Field Bone Marrow Aspirate™ (FF-BMA) Application.
-
Zylö announces the creation and spinout of Atticus Pharma Inc.
4/17/2024
Zylö recently effected a spinout of Atticus Pharma Inc., whose mission is to unlock the value of the Z-pod ® topical delivery platform in the pharmaceutical vertical.
-
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
4/17/2024
Evaxion Biotech A/S announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma received the last vaccine dose in combination with KEYTRUDA® (NCT05309421).
-
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
4/17/2024
Science 37 Holdings, Inc. today announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed, and fully consented.
-
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
4/17/2024
Ventus Therapeutics today announced results from its Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.
-
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101
4/17/2024
NRx Pharmaceuticals today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin.
-
Medline adds Epredia to lab portfolio
4/17/2024
Medline, a market-leading manufacturer and supplier of medical supplies and solutions, is pleased to announce that it is now a direct distributor for Epredia, a member of PHC Group.